info@ucallmlabs.com
Protein-RNA interaction-Pull‑down
1.1 RNA Pull‑down
1.1.1 Introduction
RNA pull‑down is an in vitro affinity‑based technique leveraging the biotin‑streptavidin interaction system for the efficient enrichment and identification of RNA‑binding proteins (RBPs). A biotin‑labeled RNA probe is generated by in vitro transcription and subsequently incubated with whole‑cell protein extracts, enabling the formation of sequence‑specific RNA‑protein complexes. These complexes are then captured by streptavidin‑coated magnetic beads and magnetically separated from unbound components in the incubation mixture. Following stringent washes to eliminate non‑specifically adsorbed contaminants, the target proteins are recovered via competitive elution (using free biotin) or denaturing elution (for downstream proteomic analysis). The eluted proteins are ultimately identified by Western blot (for validation of known RBPs) or liquid chromatography‑tandem mass spectrometry (for discovery of novel interacting proteins), thereby enabling systematic profiling of the protein repertoire associated with the RNA of interest.
1.1.2 Products
1.1.3 Applications
| Applications | Descriptions |
|---|---|
| Identification of RNA‑binding proteins | Capture and identify proteins interacting with specific RNA molecules using biotin‑labeled RNA probes from cell lysates; foundational for studying RNA functional mechanisms. |
| Study of lncRNA functional mechanisms | Elucidate how lncRNAs regulate gene expression and chromatin states via interactions with chromatin‑modifying complexes, transcription factors, and other proteins. |
| circRNA‑RBP regulatory networks | Identify circRNA‑RBP interactions to decipher circRNA functions as protein sponges or scaffolds in diseases such as cancer. |
| Analysis of RNA structure‑function relationships | Determine how specific RNA sequences or structural motifs affect protein binding and function through mutagenesis and domain deletion combined with pull‑down validation. |
| Disease mechanisms and drug target discovery | Identify disease‑associated RNA‑interacting proteins to uncover pathogenic mechanisms and provide candidate targets for small‑molecule drugs targeting RNA‑protein interactions. |
References:
- Chu C, Zhang QC, da Rocha ST, Flynn RA, Bharadwaj M, Calabrese JM, Magnuson T, Heard E, Chang HY. Systematic discovery of Xist RNA binding proteins. Cell. 2015 Apr 9;161(2):404‑16. doi: 10.1016/j.cell.2015.03.025. Epub 2015 Apr 2. PMID: 25843628; PMCID: PMC4425988.
- Lerra L, Panatta M, Bär D, Zanini I, Tan JY, Pisano A, Mungo C, Baroux C, Panse VG, Marques AC, Santoro R. An RNA‑dependent and phase‑separated active subnuclear compartment safeguards repressive chromatin domains. Mol Cell. 2024 May 2;84(9):1667‑1683.e10. doi: 10.1016/j.molcel.2024.03.015. Epub 2024 Apr 9. PMID: 38599210; PMCID: PMC11065421.
- Okholm TLH, Sathe S, Park SS, Kamstrup AB, Rasmussen AM, Shankar A, Chua ZM, Fristrup N, Nielsen MM, Vang S, Dyrskjøt L, Aigner S, Damgaard CK, Yeo GW, Pedersen JS. Transcriptome‑wide profiles of circular RNA and RNA‑binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression. Genome Med. 2020 Dec 7;12(1):112. doi: 10.1186/s13073‑020‑00812‑8. PMID: 33287884; PMCID: PMC7722315.
- Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010 Aug 6;329(5992):689‑93. doi: 10.1126/science.1192002. Epub 2010 Jul 8. PMID: 20616235; PMCID: PMC2967777.
- Trendel J, Schwarzl T, Horos R, Prakash A, Bateman A, Hentze MW, Krijgsveld J. The Human RNA‑Binding Proteome and Its Dynamics during Translational Arrest. Cell. 2019 Jan 10;176(1‑2):391‑403.e19. doi: 10.1016/j.cell.2018.11.004. Epub 2018 Dec 6. PMID: 30528433.